Dangas GD, Kini AS, Sharma SK, Henriques JPS, Claessen BE, Dixon SR, Massaro JM, Palacios I, Popma JJ, Ohman EM, Stone GW, O’Neill WW.
Impact of Hemodynamic Support with Impella 2.5 versus Intra Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial)
. Am J Cardiol 2014;113:222-228.
To compare clinical outcomes resulting from the use of the Impella 2.5 heart pump to those of the intra aortic balloon pump (IABP) during high-risk PCI.
Continue reading Study Shows High-Risk PCI with Impella Improved 90-day Event-Free Survival Compared to IABP Article
The abstract for this article was
presented by Dr. Mauricio Cohen at TCT 2015
and reported by the Protected PCI blogging team during the conference.
Cohen, et al. (2015) compared the experiences of high-risk PCI patients in the PROTECT II clinical trial with a similar group of patients treated in certain “real world” clinical settings. Patients enrolled in the now global cVAD Registry™ (formerly USpella) comprised the “real world” patient groups.
Continue reading Real-World Data Show Protected PCI Patients Had Significant CHF Symptom Improvement at Discharge
There is a growing need in the cath lab to treat more high risk patients, per the CHIP initiative. Dr. Ajay Kirtane, Dr. John Lasala, Dr. Jeff Popma and Dr. Jeff Moses discuss. Subscribe or join the conversation by following us on Twitter: @ProtectedPCI IMP-820-16
Hemodynamic Support in High Risk Patients Undergoing Extensive Revascularization: Dr. John Lasala, Dr. Jeff Moses, Dr. Bill O'Neill and Dr. Jeff Popma discuss new data from PROTECT II, the randomized trial on high risk PCI.
VIDEO Continue reading New Insights from PROTECT II Trial Discussed at TCT 2011